PEG-interferon in acute and chronic hepatitis C: a review

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) infection poses significant health risks, necessitating effective antiviral therapies.
• Pegylated interferon (PEG-IFN) alpha, in combination with ribavirin, offers a sustained eradication of HCV in 40-50% of chronic cases.
• Understanding the efficacy of PEG-IFN alpha in both acute and chronic HCV hepatitis is crucial for optimizing patient outcomes.

Purpose of the Study:

• To review and evaluate the efficacy of PEG-IFN alpha in treating acute and chronic HCV-related hepatitis.
• To delineate treatment protocols based on HCV genotype, disease stage, and patient characteristics.

Main Methods:

• Review of existing literature on PEG-IFN alpha-based therapies for HCV.
• Analysis of treatment responses in acute and chronic HCV hepatitis.
• Consideration of factors such as HCV genotype, viral load, ALT levels, and histological findings.

Main Results:

• For acute HCV hepatitis, PEG-IFN alpha-2b monotherapy or combination therapy with ribavirin shows similar efficacy.
• Optimal treatment for acute HCV involves starting therapy within 3 months of infection, with durations of 3-6 months depending on genotype.
• For chronic HCV hepatitis, combination therapy (PEG-IFN alpha-2a/2b + ribavirin) is first-line for patients with detectable HCV RNA and ALT >80 IU/L.

Conclusions:

• PEG-IFN alpha-based therapies are effective for both acute and chronic HCV hepatitis, with specific protocols for different genotypes.
• Histological evaluation is recommended for older patients (>50 years) with chronic HCV genotypes 1 or 4, and for those with stage 1 infection.
• Treatment cessation is advised if HCV RNA remains detectable after 3 months of therapy in chronic cases, indicating non-response.